Related references
Note: Only part of the references are listed.Comprehensive Sequencing of PALB2 in Patients With Breast Cancer Suggests PALB2 Mutations Explain a Subset of Hereditary Breast Cancer
Priscilla H. Fernandes et al.
CANCER (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination With Cytotoxic Chemotherapy in Pediatric Solid Tumors
Robin E. Norris et al.
PEDIATRIC BLOOD & CANCER (2014)
Integrated analysis of germline and somatic variants in ovarian cancer
Krishna L. Kanchi et al.
NATURE COMMUNICATIONS (2014)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Nataliya Zhukova et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Predicting Enhanced Cell Killing through PARP Inhibition
Julie K. Horton et al.
MOLECULAR CANCER RESEARCH (2013)
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Molecular subgroups of medulloblastoma: the current consensus
Michael D. Taylor et al.
ACTA NEUROPATHOLOGICA (2012)
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
Marcel Kool et al.
ACTA NEUROPATHOLOGICA (2012)
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
J. Chad Brenner et al.
CANCER RESEARCH (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
Gabriele Zoppoli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent
Diana Nguyen et al.
CELL CYCLE (2011)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
PALB2/FANCN: Recombining Cancer and Fanconi Anemia
Marc Tischkowitz et al.
CANCER RESEARCH (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
Remi Buisson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Structural basis for recruitment of BRCA2 by PALB2
Antony W. Oliver et al.
EMBO REPORTS (2009)
PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Fan Zhang et al.
MOLECULAR CANCER RESEARCH (2009)
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Shirley M. H. Sy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
Molecular characterization of the pediatric preclinical testing panel
Geoffrey Neale et al.
CLINICAL CANCER RESEARCH (2008)
Initial testing of cisplatin by the pediatric preclinical testing program
Mimi Tajbakhsh et al.
PEDIATRIC BLOOD & CANCER (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
Analysis of PALB2/FANCN-associated breast cancer families
Marc Tischkowitz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A recurrent mutation in PALB2 in Finnish cancer families
Hannele Erkko et al.
NATURE (2007)
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
Tomas Frgala et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2
Bing Xia et al.
NATURE GENETICS (2007)
Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer
Sarah Reid et al.
NATURE GENETICS (2007)
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
Nazneen Rahman et al.
NATURE GENETICS (2007)
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2
Blanche P. Alter et al.
JOURNAL OF MEDICAL GENETICS (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies
NLM Liem et al.
BLOOD (2004)
Share Paper
